本文選題：艾塞那肽 + 二甲雙胍��； 參考：《中國藥房》2017年12期

【摘要】：目的 :觀察艾塞那肽聯(lián)合枸櫞酸氯米芬治療多囊卵巢綜合征伴胰島素抵抗的療效和安全性。方法:98例多囊卵巢綜合征伴胰島素抵抗患者隨機分為對照組(49例)和觀察組(49例)。對照組患者給予枸櫞酸氯米芬膠囊50 mg,口服,每日1次,連用5d+二甲雙胍腸溶片首次劑量0.25 g,口服,每日2次,后調(diào)整劑量至0.50~0.75 g,口服,每日2次,連用3個月經(jīng)周期。觀察組患者給予枸櫞酸氯米芬膠囊(用法用量同對照組)+艾塞那肽注射液5μg,每日2次,皮下注射1個月,后調(diào)整劑量至10μg,每日2次,皮下注射2個月。觀察兩組患者的臨床療效,治療前后促黃體生成素(LH)、促卵泡激素(FSH)、LH/FSH和胰島素抵抗指數(shù)(IR),不孕患者治療后排卵及妊娠情況,并記錄不良反應(yīng)發(fā)生情況。結(jié)果:觀察組患者總有效率、排卵率、妊娠率均顯著高于對照組,差異均有統(tǒng)計學(xué)意義(P0.05)。治療前,兩組患者LH、FSH、LH/FSH和IR比較,差異均無統(tǒng)計學(xué)意義(P0.05)。治療后,兩組患者LH、LH/FSH、IR均顯著低于同組治療前,且觀察組顯著低于對照組;兩組患者FSH均顯著高于同組治療前,且觀察組顯著高于對照組,差異均有統(tǒng)計學(xué)意義(P0.05)。兩組患者不良反應(yīng)發(fā)生率比較,差異無統(tǒng)計學(xué)意義(P0.05)。結(jié)論:艾塞那肽聯(lián)合枸櫞酸氯米芬治療多囊卵巢綜合征伴胰島素抵抗的療效顯著,可通過改善胰島素抵抗來提高排卵率及妊娠率,且未增加不良反應(yīng)的發(fā)生。
[Abstract]:Aim: to observe the efficacy and safety of ixanapeptide combined with clomiphene citrate in the treatment of polycystic ovary syndrome with insulin resistance. Methods Ninety-eight patients with polycystic ovary syndrome with insulin resistance were randomly divided into control group (n = 49) and observation group (n = 49). In the control group, 50 mg clomiphene citrate capsule was given orally, once a day, the first dose of metformin enteric-coated tablets was 0.25 g for 5 days, twice a day, and the adjusted dose was 0.50 ~ 0.75 g, orally, twice a day, for 3 consecutive menstrual cycles. The patients in the observation group were given clomiphene citrate capsule (dosage the same as the control group) 5 渭 g, twice a day, subcutaneously for 1 month, then adjusted to 10 渭 g, twice a day, subcutaneously for 2 months. The clinical effects of the two groups were observed, including luteinizing hormone (LHN), follicle stimulating hormone (FSH), LH / FSH and insulin resistance index (IRI) before and after treatment. Ovulation and pregnancy were recorded in infertile patients after treatment, and adverse reactions were recorded. Results: the total effective rate, ovulation rate and pregnancy rate in the observation group were significantly higher than those in the control group (P 0.05). Before treatment, there was no significant difference in LHH / FSH and IR between the two groups. After treatment, the FSH of the two groups was significantly lower than that of the control group, and the FSH of the observation group was significantly higher than that of the control group, and that of the observation group was significantly higher than that of the control group (P 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P 0.05). Conclusion: Isenapeptide combined with clomiphene citrate is effective in the treatment of polycystic ovary syndrome with insulin resistance. It can improve the ovulation rate and pregnancy rate by improving insulin resistance and does not increase the occurrence of adverse reactions.
【作者單位】： 湖北中醫(yī)藥大學(xué)黃家湖醫(yī)院婦科;
【基金】：中國博士后科學(xué)基金資助項目(No.2013M542498)
【分類號】：R711.75

【相似文獻(xiàn)】

相關(guān)期刊論文 前4條

1 金萍萍;;枸櫞酸氯米芬片聯(lián)合鹽酸二甲雙胍片治療多囊卵巢綜合征不孕的療效分析[J];現(xiàn)代實用醫(yī)學(xué);2013年10期

2 李蓮;樊亞聰;王紅梅;羅亞萍;李青;;針刺聯(lián)合枸櫞酸氯米芬片對多囊卵巢綜合征排卵障礙的影響[J];河北中醫(yī);2014年08期

3 茹秀麗;馮艷萍;孟亞麗;李義飛;張紅真;;中藥人工周期聯(lián)用枸櫞酸氯米芬對32例多囊卵巢綜合征的臨床療效分析[J];時珍國醫(yī)國藥;2013年09期

4 ;[J];;年期

相關(guān)碩士學(xué)位論文 前2條

1 任安然;枸櫞酸氯米芬對多囊卵巢綜合征患者促排卵不同時機臨床療效觀察[D];濱州醫(yī)學(xué)院;2015年

2 趙學(xué)軍;枸櫞酸氯米芬用于中年男性遲發(fā)性性腺功能減退癥患者的臨床分析[D];南昌大學(xué);2012年

，

本文編號：1799606